Compare Abeona Therapeutics Inc (ABEO) vs iShares 7-10 Year Treasury Bond ETF (IEF) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs iShares 7-10 Year Treasury Bond ETF — how do they compare? Abeona Therapeutics Inc trades at $6.52 (market cap $373.32M), while iShares 7-10 Year Treasury Bond ETF trades at $93.53. The key difference: Abeona Therapeutics Inc is trading nearer its 52-week high, iShares 7-10 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| ABEO | IEF | |
|---|---|---|
Market Cap | $373.32M | — |
Sector | Health | — |
52-Week High | $7.23 | $97.99 |
52-Week Low | $4.17 | $93.11 |
Enterprise Value | $228.22M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
IEF, a US stock, trades at $93.7, down 0.45% over 24 hours, with a bearish technical signal driven by moving averages. Recent corporate actions include dividend payments scheduled for mid-2026. The stock lacks key valuation and profitability ratios in the provided data, limiting fundamental assessment. News highlights bond market dynamics and Federal Reserve policy uncertainty influencing sentiment.
The outlook for IEF is cautious due to bearish technical indicators and macroeconomic headwinds like potential rate hikes. Investment opportunities may arise from dividend distributions, but risks include market volatility and Fed policy shifts. Investors should weigh technical weakness against income potential in a fluctuating interest rate environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About iShares 7-10 Year Treasury Bond ETF
The underlying index measures the performance of public obligations of the US Treasury that have a remaining maturity of greater than or equal to seven years and less than ten years. The fund will invest at least 80% of its assets in the component securities of the underlying index, and the fund will invest at least 90% of its assets in US Treasury securities that the advisor believes will help the fund track the underlying index.
Read more on IEF →
